Tesseract Health Closes Oversubscribed $80 Million Series B Financing
Retrieved on:
星期二, 四月 20, 2021
b'Tesseract HealthTM Inc. has raised $80 million in an oversubscribed Series B financing round -- with support from investors including Foresite Capital, Glenview Capital, and Opaleye -- to advance the development of the company\xe2\x80\x99s groundbreaking Tesseract iC\xe2\x84\xa2 eye-imaging diagnostic technology platform.
Key Points:
- b'Tesseract HealthTM Inc. has raised $80 million in an oversubscribed Series B financing round -- with support from investors including Foresite Capital, Glenview Capital, and Opaleye -- to advance the development of the company\xe2\x80\x99s groundbreaking Tesseract iC\xe2\x84\xa2 eye-imaging diagnostic technology platform.
- View the full release here: https://www.businesswire.com/news/home/20210420005215/en/\nTesseract Health\xe2\x84\xa2 Inc. has raised $80 million in an oversubscribed Series B financing round to advance the development of the company\xe2\x80\x99s groundbreaking Tesseract iC\xe2\x84\xa2 eye-imaging diagnostic technology platform.
- The Tesseract iC platform (not yet cleared by the US FDA) is intended to diagnose a wide range of diseases without drawing blood.
- This future will be made possible by Tesseract Health and its innovative Tesseract iC platform incorporating novel multidimensional sensors and artificial intelligence.